HS
COGT icon

HighVista Strategies’s Cogent Biosciences COGT Stock Holding History

HighVista Strategies’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.31M Sell
188,780
-8,271
-4% -$289K 1.67% 12
2026
Q1 		$7.58M Sell
197,051
-139,616
-41% -$5.16M 2.09% 4
2025
Q4 		$12M Sell
336,667
-125,738
-27% -$3.53M 3.08% 3
2025
Q3 		$6.64M Buy
462,405
+179,219
+63% +$2.12M 1.63% 14
2025
Q2 		$2.03M Buy
283,186
+3,513
+1% +$19.5K 0.75% 42
2025
Q1 		$1.68M Hold
279,673
– – 0.65% 53
2024
Q4 		$2.18M Buy
279,673
+54,040
+24% +$539K 0.81% 40
2024
Q3 		$2.44M Sell
225,633
-55,460
-20% -$540K 0.84% 35
2024
Q2 		$2.37M Hold
281,093
– – 0.87% 34
2024
Q1 		$1.89M Hold
281,093
– – 0.67% 51
2023
Q4 		$1.65M Buy
281,093
+82,506
+42% +$632K 0.6% 58
2023
Q3 		$1.94M Sell
198,587
-17,543
-8% -$208K 0.9% 36
2023
Q2 		$2.56M Buy
216,130
+32,146
+17% +$369K 1.17% 27
2023
Q1 		$1.99M Hold
183,984
– – 1.62% 22
2022
Q4 		$2.13M Buy
183,984
+65,049
+55% +$806K 1.26% 23
2022
Q3 		$1.77M Buy
+118,935
New +$1.63M 1.01% 32

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HighVista Strategies's COGT Position: Q2 2026 in Review

HighVista Strategies reduced its Cogent Biosciences (COGT) stake by 4.2% in Q2 2026, selling an estimated $289K and leaving 188,780 shares worth $7.31M. The position accounts for 1.67% of the portfolio, ranked #12.

HighVista Strategies first reported a position in COGT in Q3 2022 and has held it in 16 quarters since. The position peaked at $12M in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • HighVista Strategies held 188,780 shares of Cogent Biosciences worth $7.31M as of Q2 2026.
  • HighVista Strategies sold 8,271 Cogent Biosciences shares in Q2 2026, an estimated $289K.
  • Cogent Biosciences made up 1.67% of HighVista Strategies's portfolio in Q2 2026, its #12 holding.
  • HighVista Strategies first reported a position in Cogent Biosciences in Q3 2022 and has held it in 16 quarters since.
  • HighVista Strategies's Cogent Biosciences position peaked at $12M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.